2000-2004

2004

• Honer M., Bruehlmeier M., Missimer J., Schubiger P.A., Ametamey S.M. Dynamic Imaging of striatal D2 receptors in mice using Quad-HIDAC PET. J. Nucl. Med., 45, 464-470 (2004).

• Missimer J., Madi Z., Honer M., Keller C., Schubiger P.A., Ametamey S.M. Performance evaluation of the 16-module quad-HIDAC small animal PET camera. Phys. Med. Biol., 49, 2069-2081 (2004).

• Itier V., Schonbachler R., Tribollet E., Honer M., Prinz K., Marguerat A., Bertrand S., Bunnelle W.H., Schubiger P.A., Meyer M. D., Sullivan J.P., Bertrand D., Westera G. A-186253, a specific antagonist of the alpha 4 beta 2 nAChRs: its properties and potential to study brain nicotinic acetylcholine receptors. Neuropharmacology, 47, 538-557 (2004).

• Krasikova R.N., Zaitsev V.V., Ametamey S.M., Kuznetsova O.F., Fedorova O.S., Mosevich I.K., Belokon Y.N., Vyskocil S., Shatik S.V., Nader M., Schubiger P.A. Catalytic enantioselective synthesis of 18F-fluorinated α-amino acids under phase-transfer conditions using (S)-NOBIN. Nucl. Med. Biol., 31, 597-603 (2004).

• Heiz M., Grünberg J., Schubiger P.A., Novak-Hofer I. Hepatocyte growth factor-induced ectodomain shedding of cell adhesion molecule L1. J. Biol. Chem., 279, 31149-31156 (2004).

• Wyss M., Weber B., Honer M., Späth N., Ametamey S.M, Westera G., Bode B., Kaim A., Buck A. 18F-Choline in experimental soft tissue infection assessed with autoradiography and high resolution PET. Eur. J. Nucl. Med. Mol. Imaging, 31, 312-316 (2004).

• Francis R.J., Mather S.J., Chester K., Sharma S.K., Bhatia J., Pedley R.B., Waibel R., Green A.J., Begent R.H.J. Radiolabelling of glycosylated MFE-23::CPG2 fusion protein (MFECP1) with 99mTC for quantitation of tumour antibody-enzyme localisation in antibody-directed enzyme pro-drug therapy (ADEPT). Eur. J. Nucl. Med. Mol. Imaging, 31, 1090-1096 (2004).

• Wyss M.T., Honer M., Späth N., Gottschalk J., Ametamey S.M., Weber B., von Schulthess G.K., Buck A., Kaim A. Influence of ceftriaxone treatment on FDG uptake – an in vivo [18F]-Fluorodeoxyglucose imaging study in soft tissue infections in rats. Nucl. Med. Biol., 31, 875-882 (2004).

• Tenzer A., Hofstetter B., Sauser C., Bodis S., Schubiger P.A., Bonny C., Pruschy M. Profiling treatment-specific post-translational modifications in a complex proteome with substractive substrate phage display. Proteomics, 4, 2796-2804 (2004).

• VanBrocklin H.F., Blagoev M., Hoepping A., O’Neil J.P., Klose M., Schubiger P.A., Ametamey S. A new precursor for the preparation of 6-[18F]fluoro-L-m-tyrosine ([18F]FMT): Efficient synthesis and comparison of radiolabeling. Appl. Radiat. Isot., 61, 1289-1294 (2004).

• Allemann K., Wyss M., Wergin M., Rohrer C., Ametamey S.M., Brühlmeier M., Kaser-Hotz B. Positronen-Emissions-Tomographie, ein bildgebendes Verfahren auf molekularer Ebene. Schweizer Archiv für Tierheilkunde, 146, 359-364 (2004).

• Bruehlmeier M., Roelcke U., Schubiger P.A., Ametamey S.M. Assesment of hypoxia and perfusion in human brain tumors using PET with 18F-fluoromisonidazole and 15O-H2O. J. Nucl. Med., 45, 1851-1859 (2004).

• Bläuenstein P., Garcia-Garayoa E., Rüegg D., Blanc A., Tourwé D., Beck-Sickinger A., Schubiger P.A. Improving the tumor uptake of 99mTc-labeled neuropeptides using stabilized peptide analagues. Cancer Biother. Radiopharm., 19, 181-188 (2004).

• Müller C., Dumas C., Hoffmann U., Schubiger P.A., Schibli R. Organometallic 99mTc-technetium (I) and Re-rhenium(I)-folate derivatives for potential use in nuclear medicine. J. Organomet. Chem., 689, 4712-4721 (2004).

• Raic-Malic S., Johayem A., Ametamey S.M., Batinac S., De Clerk E., Folkers G., Scapozza L. Synthesis, 18F-radiolabelling and biological evaluations of C-6 alkylated pyrimidine nucleoside analogues. Nucleosides, Nucleotides & Nucleic Acids, 23, 1707-1721 (2004).

• Gorshkov N.I., Schibli R., Schubiger A.P., Lumpov A.A., Miroslavov A.E., Suglobov D.N. "2+1" Dithiocarbamate-isocyanide chelating systems for linking M(CO)(3)(+) (M=99(m)Tc, Re) fragment to biomolecules. J. Organomet. Chem., 689, 4757-4763 (2004).

• van Staveren D.R., Waibel R., Mundwiler S., Schubiger P.A., Alberto R. Conjugates of vitamin B12 with Ne-functionalized histidine for labeling with [99mTc(OH2)3(CO)3]+: synthesis and biodistribution studies in tumor bearing mice. J. Organomet. Chem., 689, 4803-4810 (2004).

2003

• Schibli R., Netter M., Scapozza L., Birringer M., Schelling P., Dumas C., Schoch J., Schubiger P.A. First organometallic inhibitors for human thymidine kinase: synthesis and in vitro evaluation rhenium(I)- and technetium(I)-tricarbonyl complexes of thymidine. J. Org. Chem., 68, 67-74 (2003).

• Dumas C., Schibli R., Schubiger P.A. Versatile routes to C-(2) and C-(6) functionalized glucose derivatives of iminodiacetic acid. J. Org. Chem., 68, 512-518 (2003).

• Buchegger F., Bonvin F., Kosinski M., Schaffland A.O., Prior J., Reubi J.C., Bläuenstein P., Tourwé D., García Garayoa E., Bischof Delaloye A., Radiolabeled Neurotensin Analog, 99mTc-NT-XI, evaluated in Ductal Pancreatic Adenocarcinoma Patients. J. Nucl. Med., 44, 1649-1654 (2003)

• Novak-Hofer I., Honer M., Ametamey S., Grünberg J., Missimer J., Zimmermann K., Schubiger P.A. Imaging of renal carcinoma xenografts with 64Cu-labelled anti-L1-CAM antibody chCE7. Eur. J. Nucl. Med. Mol. Imaging, 30, 1066 (2003).

• Zimmermann K., Grünberg J., Honer M., Ametamey S.M., Schubiger P.A., Novak-Hofer I. Targeting of renal carcinoma with 67/64Cu-labeled anti-L1-CAM antibody chCE7: selection of copper ligands and PET imaging. Nucl. Med. Biol., 30, 417-427 (2003).

• Stichelberger A., Waibel R., Dumas C., Schubiger P.A., Schibli R. Versatile synthetic approach to new bifunctional chelating agents tailor made for labeling with the fac-[M(CO)3]+ core (M = Tc, 99mTc, Re): synthesis, in vitro, and in vivo behaviour of the model complex [M(APPA)(CO)3] (APPA = [(5-amino-pentyl)-pyridin-2-yl-methyl-amino]-acetic acid). Nucl. Med. Biol., 30, 465-470 (2003).

• Buchegger F., Vieira J.M., Bläuenstein P., Dupertuis Y.M., Schaffland A.O., Grannavel C., de Tribolet N., Slosman D.O., Bischof Delaloye A. Preclinical auger and gamma radiation dosimetry for fluorodeoxyuridine-enhanced tumor proliferation scintigraphy with [123I]iododeoxyuridine. Eur. J. Nucl. Med., 30, 239-246 (2003).

• Bruehlmeier M., Roelcke U., Bläuenstein P., Missimer J., Schubiger P.A., Locher J.Th., Pellika R. Ametamey S.M. Measurement of the Extracellular Space in Brain Tumors using 76Br-Bromide and PET. J. Nucl. Med., 44, 1210-1218 (2003).

• Di Paolo C., Willuda J., Kubetzko S., Lauffer I., Tschudi D., Waibel R., Plückthun A., Stahel R.A., Zangemeister-Wittke U. A recombinant immunotoxin derived from a humanized epithelial cell adhesion molecule-specific single-chain antibody fragment has potent and selective antitumor activity. Clin. Cancer Res., 9, 2837-2848 (2003). Erratum in: Clin. Cancer Res., 10, 2579 (2004).

• Grünberg J., Knogler K., Waibel R., Novak-Hofer I. High-yield production of recombinat antibody fragments in HEK-293 cells using sodium butyrate. Biotechniques 34, 968-972 (2003).

• Deyev S.M., Waibel R., Lebedenko E.N., Schubiger P.A., Plückthun A. Design of multivalent complexes using the barnase-barstar module. Nat. Biotechnol., 21, 1486-1492 (2003).

2002

• Schönbächler R., Gucker P.M., Arigoni M., Kneifel S., Vollenweider F.X., Buck A., Burger C., Berthold T., Schubiger P.A. and Ametamey S. PET imaging of dopamine transporters in the human brain using [11C]-b-CPPIT, a cocaine derivative lacking the 2b-ester function. Nucl. Med. Biol., 29, 19-27 (2002).

• Ametamey S.M., Kneifel S., Bruehlmeier M., Kokic M., Honer M., Arigoni M., Buck A., Burger C., Samnick S., Quack G. and Schubiger P.A. PET studies of 18F-memantine in healthy volunteers. Nucl. Med. Biol., 29, 227-231 (2002).

• Bruehlmeier M., Garcia Garayoa E., Blanc A., Tourwé D., Schubiger P.A., Bläuenstein P. Stabilization of neurotensin analogues: effect on peptide catabolism, biodistribution and tumor binding. Nucl. Med. Biol., 29, 321-327 (2002).

• La Bella R., Garcia-Garayoa E., Langer M., Bläuenstein P., Beck-Sickinger A.G., Schubiger P.A. In vitro and in vivo evaluation of a 99mTc(I)-labeled bombesin analogue for imaging of gastrin releasing peptide receptor-positive tumors. Nucl. Med. Biol., 29, 553-560 (2002).

• Garcia-Garayoa E., Bläuenstein P., Bruehlmeier m:, Blanc A., Iterbeke K., Conrath P., Tourwé D., Schubiger P.A. Preclinical evaluation of a new stabilized neurotensin (8-13) pseudopeptide radiolabeled with Tc-99m. J. Nucl. Med., 43, 374-383 (2002).

• Baumeister J.M., Alberto R., Ortner K., Spingler B., Schubiger P.A., Kaden T.A. Central vs. peripheral Ag(I) coordination in NS3-open chain and cage ligands. J. Chem. Soc., Dalton Trans., 22, 4143-4151 (2002).

• Curt A., Brühlmeier M., Leenders K.L., Roelcke U., Dietz V. Differential effect of spinal cord injury and functional impairment on human brain activation. J. of Neurotrauma, 19, 43-51 (2002).

• Ziak M., Meier M., Novak-Hofer I., Roth J. Ceruloplasmin carries the anionic glycan oglio/poly a2,8 deaminoneuraminic acid. Biochem. Biophys. Res. Comm., 295, 597-602 (2002).

• Schibli R., Schubiger P.A. Current use and future potential of organometallic radiopharmaceuticals. Eur. J. Nucl. Med. Mol. Imaging, 29, 1529-1542 (2002).

• Novak-Hofer I., Schubiger P.A. Copper-67 as a therapeutic nuclide for radioimmunotherapy. Eur. J. Nucl. Med. Mol. Imaging, 29, 821-830 (2002).

• Schibli R., Schwarzbach R., Ortner K., Schmalle H., Dumas C., Alberto R., Egli A., Schubiger P.A. Steps toward high specific activity labeling of biomolecules for therapeutic application: Preparation of precursor [188RE(H2O)3(CO)3]+ and synthesis of tailer made bifunctional ligand systems. Bioconjug. Chem., 13, 750-756 (2002).

• La Bella R., Garcia-Garayoa E., Bähler M., Bläuenstein P., Schibli R., Conrath P., Tourwé D., Schubiger P.A. A 99mTc(I)-postlabeled high affinity bombesin analogue as a potential tumor imaging agent. Bioconjug. Chem. 13, 599-604 (2002).

• Kokic M., Honer M., Kessler L., Grauert M., Schubiger P.A., Ametamey S.M. Synthesis and in vitro and in vivo evaluation of 11C-Methyl-BIII277CL for imaging the PCP binding site of the NMDA receptor by PET. J. Recept. Signal Trans. Res., 22, 123-139 (2002).

2001

• Gardelle O., Roelcke U., Vontobel P., Nigel E.A. Crompton, Guenther I., Bläuenstein P., Schubiger P.A., Blattmann H., Ryser J.E., Leenders K.L., Kaser-Hotz B. [76Br]bromodeoxyuridine PET in tumor-bearing animals. Nucl. Med. Biol., 28, 51-57 (2001).

• Hoefnagel C.A., Rutgers M., Buitenhuis C.K.M., Smets L.A., de Kraker J., Meli M., Carrel F., Amstutz H., Schubiger P.A., Novak-Hofer I. A comparison of targetting of neuroblastoma with mIBG and anti L1-CAM antibody chCE7: therapeutic efficacy in a neutoblastoma xenograft model and imaging of neuroblastoma patients. Eur. J. Nucl. Med., 28, 359-368 (2001).

• Patt J.P., Spang J.E., Buck A., Cristina H., Arras M., Schubiger P.A. and Westera G. Synthesis and in vivo studies of the stereoisomers of [C-11]N-methylhomoepibatidine. Nucl. Med. Biol., 28, 645-655 (2001).

• Willuda J., Kubetzko S, Waibel R., Schubiger P.A., Zangmeister-Wittke U, Plückthun A Tumor targeting of mono-, di-, and tetravalent anti-p185HER-2 miniantibodies multimerized by self-associating peptides. J. Biol. Chem., 276, 14485-14392 (2001).

• Petrig J., Schibli R., Dumas C., Alberto R., Schubiger P.A. Derivatization of glucose and 2-deoxyglucose for transition metal complexation: Substitution reactions with organometallic 99mTc and Re precursors and fundamental NMR investigations. Chem. Eur. J., 7, 1868-1873, (2001).

• Tenzer A., Zingg D., Rocha S., Fabbro D., Rogenmoser C., Glanzmann C., Schubiger P.A., Bodis S., Pruschy M. The PI-3K/Akt survival pathway is a target for the anticancer and radiosensitizing agent PKC412, an inhibitor of PKC α,β,γ. Cancer Res., 61, 8203-8210 (2001).

• Wong C., Waibel R., Sheets M., Mach J.P., Finnern R. Human scFv antibody fragments specific for the epithelial tumor marker MUC-1, selected by phage display on living cells. Cancer Immunol. Immunother., 50, 93-101 (2001).

• Schibli R., Katti K.V., Volkert W.A., Barnes C.L. Development of novel water-soluble, organometallic compounds for potential use in nuclear medicine: Synthesis, characterization and 1H and 31P NMR investigations of the complexes fac-[ReBr(CO3L] (L=Bis(bis(hydroxymethyl)phosphino)ethane, Bis(bis(hydroxymethyl)phosphino)benzene). Inorg. Chem., 40, 2358-2362 (2001).

• Novak-Hofer I., Zimmermann K., Schubiger P.A. Peptide linkers lead to modification of liver metabolism and improved tumor targeting of 67-Cu-labeled antibody fragments. Cancer Biother. Radiopharm., 16, 469-481 (2001).

• Alberto R., Ortner K., Wheatley N., Schibli R., Schubiger P.A. Synthesis and properties of boranocarbonate: A convenient in situ CO source for the aqueous preparation of [99mTc(OH2)3(CO)3]+. J. Am. Chem. Soc., 123, 3135-3136 (2001).

• Kukis D.L., Novak-Hofer I., DeNardo S.J. Cleavable linkers to enhance selectivity of antibody-targeted therapy of cancer. Cancer Biother. Radiopharm., 16, 457-467 (2001).

• Langer M., La Bella R., Garcia-Garayoa E., Beck-Sickinger A.G. Tc-99m-labeled neuropeptide Y analogues as potential tumor imaging agents. Bioconjug. Chem. 12, 1028-1034 (2001).

• Rattat D., Schubiger P.A., Berke H.G., Schmalle H., Alberto R. Dicarbonyl-nitrosyl-complexes of rhenium (Re) and technetium (Tc), a potentially new class of compounds for the direct radiolabeling of biomolecules. Cancer Biother. Radiopharm., 16, 339-343 (2001).

• Storto G., Buchegger F., Waibel R., Kuenzi G., Offord R.E., Schubiger P.A., Gillet M., Bischof Delaloye A. Biokinetics of a F(ab’)3 iodine-131 labeled antigen binding construct (MAb 35) directed against CEA in patients with colorectal carcinoma. Cancer Biother. Radiopharm., 16, 371-379 (2001).

• Garcia-Garayoa E., Allemann-Tannahill L., Bläuenstein P., Willmann M., Carrel-Rémy N., Tourwé D., Iterbeke K., Conrath P., and Schubiger P.A., In vitro and in vivo evaluation of new radiolabelled neurotensin (8-13) analogues with high affinity for NT1 receptors. Nucl. Med. Biol., 28, 75-84 (2001).
  

2001

• Spang J.E., Patt J.T., Westera G., Schubiger P.A. Comparision of N-[11C]methyl-norchloroepibatidine and N-[11C]methyl-2(2-pyridyl)-7-azabicyclo [2.2.1]heptane with N-[11C]methyl-epibatidine in small animals PET studies. Nucl. Med. Biol., 27, 239-247 (2000).

• Ametamey S.M, Kokic M., Carrel-Rémy N., Bläuenstein P., Willmann M., Bischoff S., Schmutz M., Schubiger P.A., Auberson Y.P. Synthesis, radiolabelling and biological characterization of (D)-7-iodo-N-(1-phosphonoethyl)-5-aminomethylquinoxaline-2,3-dione, a glycine-binding site antagonist of NMDA receptors. Bioorg. Med. Chem. Lett., 10, 75-78 (2000).

• Patt J.T., Spang J.E., Westera G, Schubiger P.A. [C-11]N-methylhomoepibatidine: Radiolabelling and biodistribution studies in mice. J. Lab. Comp. Radiopharm., 43, 127-136 (2000).

• Hughes  O.D.M, Bishop M.C., Perkins A.C, Wastie M.L., Denton G., Price M.R., Frier M., Denley H., Rutherford R., Schubiger P.A. Targeting superficial bladder cancer by the intravesical administration of copper-67-labeled anti-MUC1 mucin monoclonal antibody C595. J. Clin. Oncol., 18, 363-370 (2000).

• Buck A., Gucker P.M., Schönbächler R.D., Arigoni M., Kneifel S., Vollenweider F.X., Ametamey S.M. and Burger C. Evaluation of serotonergic transporters using PET and [11C](+)McN-5652: Assessment of methods. J. Cereb. Blood Flow Metab., 20, 253-262 (2000).

• Zurbriggen R., Novak-Hofer I., Seelig A., Glück R. IRIV-adjuvanted hepatitis A vaccine: in vivo absorption and biophysical characterization. Prog. Lipid Res., 39, 3-18 (2000).

• Aebischer N., Schibli R., Alberto R. and Merbach A. Complete carbonylation of fac-[Tc(H2O)3(CO)3]+ under CO pressure in aqueous media: A single sample story! Angew. Chem. Int. Ed., 39, 254-256 (2000).

• Curtis L., Chiodini F., Spang J.E., Bertrand S., Patt J.T., Westera G., Bertrand D. A new look at the nicotinic acetylcholine receptor phamacophore. Eur. J. Pharmacology, 393, 155-163 (2000).

• Millet P., Graf C., Buck A., Walder B., Westera G., Broggini C., Arigoni M., Slosman D., Bouras C., Ibanez V. Similarity and robustness of PET and SPECT binding parameters for benzodiazepine receptors. J. Cereb. Blood Flow and Metab., 20, 1587-1603 (2000).

• Millet P., Graf C., Buck A., Walder B., Westera G., Broggini C., Arigoni M, Slosman D., Bouras C., Ibanez V. Similarity and robustness of PET and SPECT binding parameters for benzodiazepine receptors. J. Cereb. Blood Flow and Metab., 20, 1587-1603 (2000).

• Bruehlmeier M., Leenders K.L., Vontobel P., Calonder C., Antonini A., Weindl A., Increased cerebral Iron uptake in Wilson’s Disease: A52Fe-citrate PET study. J. Nucl. Med., 41, 781-787 (2000).

• Schibli R., La Bella R., Alberto R., Garcia-Garayoa E., Kirstin O., Abram U, Schubiger P.A. Influence of the denticity of ligand systems on the in vitro and in vivo behaviour of 99mTc(I)-tricarbonyl complexes: A hint for the future functionalization of biomolecules. Bioconjug. Chem., 11, 345-451 (2000).

• Spang J.E., Bertrand S., Westera G., Patt J.T., Schubiger P.A., Bertrand D. Chemical modification of epibatidine causes a switch from agonist to antagonist and modifies its selectivity for neuronal nicotinic acetylcholine receptors. Chem. Biol., 7, 545-555 (2000).

• Pietsch H.J., Gupta A., Reisgys M., Drews A, Seifert S., Syhre R., Spess H., Alberto R., Abram, U., Schubiger P.A., Johannsen B. Chemical and biological characterization of technetium (I) and rhenium (I) tricarbonyl complexes with dithioether ligands serving as sinkers for coupling the Tc(CO)3 and Re(CO)3 moieties to biologically active molcules. Bioconjug. Chem., 11, 414-424 (2000).